Viridian Therapeutics (NASDAQ:VRDN) Releases Earnings Results, Beats Estimates By $0.24 EPS

Viridian Therapeutics (NASDAQ:VRDN) issued its earnings results on Thursday. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24, Zacks reports. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%.

Viridian Therapeutics Price Performance

Shares of VRDN stock traded down $0.24 during trading hours on Thursday, hitting $15.29. 783,003 shares of the company’s stock were exchanged, compared to its average volume of 1,109,766. The stock’s 50-day moving average is $18.34 and its 200-day moving average is $19.66. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -3.55 and a beta of 1.32. Viridian Therapeutics has a 52 week low of $11.40 and a 52 week high of $27.20.

Wall Street Analyst Weigh In

A number of research analysts recently commented on VRDN shares. Needham & Company LLC restated a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Royal Bank of Canada upped their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Tuesday, December 17th. TD Cowen initiated coverage on Viridian Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating on the stock. Finally, Wells Fargo & Company reiterated an “equal weight” rating and issued a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Viridian Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $35.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.